Gilead’s remdesivir is the people’s remdesivir, AGs say
Dozens of state attorneys general have written to the Department of Health and Human Services, urging it to exercise “march-in” rights to sidestep the patents for Gilead’s Covid-19 drug, remdesivir.
Their argument, according to STAT’s Ed Silverman: To develop the treatment, Gilead has benefited from millions of dollars in public funding — and is “unable to guarantee a supply of remdesivir sufficient to alleviate the health and safety needs of the country amid the pandemic.”
Gilead might beg to differ. And it’s worth remembering that it might have more than a little on the line. Michael Yee at Jefferies recently suggested potential remdesivir sales could reach $2.4 billion or more this year or next year.
Read more.
Their argument, according to STAT’s Ed Silverman: To develop the treatment, Gilead has benefited from millions of dollars in public funding — and is “unable to guarantee a supply of remdesivir sufficient to alleviate the health and safety needs of the country amid the pandemic.”
Gilead might beg to differ. And it’s worth remembering that it might have more than a little on the line. Michael Yee at Jefferies recently suggested potential remdesivir sales could reach $2.4 billion or more this year or next year.
Read more.
.png)
No hay comentarios:
Publicar un comentario